Table 7Priors for natural history transition matrix

NBOBarLGDHGDCanaCansDead
NBO0.120.2400000
Bar0.120.120.120.240.2400
LGD0.240.120.120.120.2400
HGD0.240.240.120.120.1200
Cana00000.120.120
Cans000000.120.12
Dead0000000

NBO = no Barrett’s oesophagus; BAR = non-dysplastic Barrett’s oesophagus; LGD = low grade dysplasia; HGD = high grade dysplasia; cana = asymptomatic cancer; cans; symptomatic cancer

From: Appendix 6, Cost effectiveness analysis for Barrett’s oesophagus

Cover of Barrett’s Oesophagus
Barrett’s Oesophagus: Ablative Therapy for the Treatment of Barrett’s Oesophagus.
NICE Clinical Guidelines, No. 106.
Centre for Clinical Practice at NICE (UK).
Copyright © 2010, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.